6 results about "Soluble Tablet" patented technology

The invention discloses a Ganoderma sinense flash-soluble tablet and a preparation method thereof, and belongs to the technical field of food health care, Ganoderma sinense sporocarp is subjected to deproteinization treatment to prevent precipitation generated by combination of tannic acid and Ganoderma sinense protein, and polysaccharide and triterpenes in Ganoderma sinense sporocarp are effectively retained and enriched after Ganoderma sinense sporocarp superfine powder is subjected to deproteinization treatment. In the preparation process, tannic acid serves as a structure trigger and is self-assembled with ganoderma sinense polysaccharide in deproteinized ganoderma sinense powder through hydrogen bonds to form a pH responsive hydration film, phenolic hydroxyl groups of tannic acid and alcoholic hydroxyl groups of beta-glucan form a multiple hydrogen bond network, aromatic rings are embedded into hydrophobic cavities of beta-glucan, and the compound is stabilized through the hydrophobic effect. By adopting hydroxypropyl-beta-cyclodextrin inclusion, the tannic acid is prevented from being combined with the ganoderma sinense sporocarp protein to form a precipitate in space. The Ganoderma sinensis flash-soluble tablet prepared by the invention is rich in triterpenes and polysaccharide components, can significantly improve immunity and regulate intestinal flora, and is suitable for health food development.

The utility model provides a gibberellic acid soluble tablet preparation device, and belongs to the technical field of gibberellic acid soluble tablet preparation. Comprising a reaction barrel; the mixing part is positioned in the reaction barrel, is used for mixing the gibberellic acid material with other ingredients, and is set to release the mixed material to the next working procedure after the mixing is finished; the crushing part is positioned in the reaction barrel and is used for crushing the mixed material released by the mixing part; the transmission part is positioned in the reaction barrel and is used for driving the mixing part or the crushing part to rotate; the driving part is located at the top end of the reaction barrel and used for driving the transmission part to rotate. By arranging the mixing part and the crushing part, the mixing part and the crushing part of the novel device are both arranged in the reaction barrel, and are directly switched to a crushing procedure through an internal transmission structure after mixing is completed, so that material transfer is not needed, the possibility that external impurities are mixed into mixed materials is greatly reduced, the purity of gibberellic acid products in the production process is ensured, and the production efficiency of gibberellic acid products is improved. And the product quality is improved.

The invention discloses a water-soluble solid insecticide and a preparation method thereof, the insecticide is a water-soluble tablet or granule, and the insecticide comprises the following components in percentage by mass: 30-80% of thiocyclam, 0-30% of an insecticide B, 0.1-2% of a pH regulator, 0.1-0.5% of an attractant, 1-20% of a surfactant and the balance of filler. The preparation method comprises the steps of material mixing, airflow crushing, water adding and kneading, forming, drying, screening and packaging. The insecticide disclosed by the invention adopts a water-soluble tablet or granule and is free from precipitation after being dissolved in water, so that the environmental pollution in the production and use processes is reduced, the shelf life of the product is prolonged, and the lasting period for preventing and treating harmful insects of crops can be prolonged.

This application discloses nalmefene base, its preparation method, and its application, belonging to the field of pharmaceutical technology. The preparation method of nalmefene includes the following steps: mixing nalmefene hydrochloride with water to form an aqueous solution of nalmefene hydrochloride; reacting the aqueous solution of nalmefene hydrochloride with an aqueous solution of an alkaline component to form nalmefene base; the pH of the nalmefene hydrochloride is 4.0-6.5; the alkaline component includes at least one selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium acetate, ammonia, and sodium dihydrogen phosphate. This application uses nalmefene hydrochloride with a pH of 4.0-6.0 to undergo a desalting reaction with an aqueous solution of a strong base-weak acid salt or a weak base, crystallizing out nalmefene base. This effectively controls the particle size and shape of nalmefene base, obtaining small-particle-size, low-content, stable, and poorly soluble tablet-shaped nalmefene base without pulverization. It is less prone to burst release, meeting the requirements for sustained-release formulations, and the reaction is mild, green, and economical.

Described herein are formulations of a peptide derived from Chaperonin 60.1 suitable for sublingual administration. A dissolvable tablet pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This dissolvable tablet formulation includes a matrix-forming agent, a surfactant, a pH modifier, and a solvent. It may also contain sweeteners, flavor enhancers, or flavoring agents. In addition, a liquid pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This liquid pharmaceutical formulation includes the peptide, bovine serum albumin, and phosphate-buffered saline. The sublingual formulations achieve rapid systemic delivery comparable to IV administration. These formulations are intended for treating inflammatory conditions through sublingual administration. The formulations can be used for various inflammatory conditions and are adaptable for different administration frequencies and subject types.

The application belongs to the technical field of medicine, and specifically provides an entero-soluble ibrexin tablet with high bioavailability and a preparation method thereof. The entero-soluble tablet comprises a tablet core and an enteric coating, wherein the tablet core comprises an ibrexin coating compound, microcrystalline cellulose and magnesium stearate, and the ibrexin coating compound comprises ibrexin or a pharmaceutically acceptable salt thereof, an acid regulator, povidone and cross-linked sodium carboxymethyl cellulose. The ibrexin entero-soluble tablet of the application can make the drug reach the end of the small intestine or the colon for release, thereby avoiding the metabolism of cytochrome P450 (CYP) 3A, and at the same time, the acid regulator can locally provide an acidic environment for the active ingredient, so that the ibrexin is rapidly dissolved and released, and the side effects such as vomiting in the gastrointestinal tract are reduced.